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Objective. There is an asymmetric allocation of technology and other resources for infertility services. Intrauterine insemination
(IUI) is a process of placing washed spermatozoa transcervically into the uterine cavity for treatment of infertility. This is a review
of literature for the potential use of IUI as a basic infertility treatment in technology-limited settings. Study design. Review of
articles on treatment of infertility using IUI. Results. Aspects regarding the use of IUI are reviewed, including ovarian stimulation,
semen parameters associated with good outcomes, methods of sperm preparation, timing of IUI, and number of inseminations.
Implications of the ﬁnding in light of the needs of low-technology medical settings are summarized. Conclusion.T h er e v i e w e d
evidence suggests that IUI is less expensive, less invasive, and comparably eﬀective for selected patients as a ﬁrst-line treatment
for couples with unexplained or male factor infertility. Those couples may be oﬀered three to six IUI cycles in technology-limited
settings.
Copyright © 2009 A. M. Abdelkader and J. Yeh.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Intrauterine insemination (IUI) is the therapeutic process of
placing washed spermatozoa transcervically into the uterine
cavity for the treatment of infertility. IUI theoretically allows
a relatively higher number of motile spermatozoa to reach
the oocyte [1]. The rationale for washing sperm is to remove
prostaglandins, infectious agents, and antigenic proteins as
well as to remove immotile spermatozoa, leucocytes, and
immaturegermcells.Theprocessallowstheconcentrationof
spermatozoainasmallvolumeofculturemediaandthenthe
concentrated spermatozoa is placed into the uterus through
a transcervical catheter.
The general process of artiﬁcial insemination has been
usedtotreatavarietyofphysiologicalandpsychologicalmale
and female infertility disorders such as severe hypospadius,
retrograde ejaculation, impotence, and vaginismus. IUI, in
the past, has been used as treatment for poor postcoital
tests and immunologic infertility [2]. Currently, IUI is used
to treat moderate male factor infertility and unexplained
infertility. Another common use of IUI is to enhance the
eﬃcacy of treatment by ovulation induction for ovulatory
disorders [1]. The simple and noninvasive nature of IUI
has allowed it to be performed by nurses in some centers
with analogous pregnancy rates to the procedures performed
by physicians [3]. Factors that may inﬂuence IUI outcome
include theuse ofovulation induction agents,semenanalysis
parameters, techniques used for sperm preparation, and the
timing and number of inseminations.
The resource allocation for advanced infertility services
is asymmetric, with the expertise and technology more con-
centrated in the larger cities and resource-rich westernized
countries [4]. In this review, we address the clinical situation
in the majority of the occasions, in which the infertility
technology that is available for treatment of patients may
be limited. Outside the technologically advanced centers,
the majority of the infertility patients have fewer options
for treatment. The roles for IUI and considerations for
its advantageous use in this limited technology setting are
considered in this manuscript. This review is divided into
two parts. In the ﬁrst, the eﬃcacy and cost-eﬀectiveness of
IUI are discussed, and, in the second part, the evidence is
presented for the beneﬁcial clinical practice of IUI in limited
technology settings.2 Obstetrics and Gynecology International
2. InfertilityandIts Economic and
Psychological Impacts
Infertility is deﬁned as failure to achieve pregnancy for
one year or more without use of contraception during
the childbearing period and aﬀects approximately 10–15%
of couples [5]. In 1995, The National Survey of Family
Growth reported that 9.3 million women between 15–
44 years (15% of women of reproductive age) made use
of infertility services in the United States. These services
included medical advice, testing for both couples, drugs for
ovulation induction, corrective surgery for tubal blockage,
and assisted reproductive technologies (ARTs) [6]. The costs
ofinfertilityevaluationandtherapywereevaluatedinastudy
conducted by Stovall et al. [7]. They found that the costs of
infertilityservicesrangedfrom0.36to1.03%ofatotalhealth
care plan with an average of 0.8%. In a 3-year period, they
found that infertility cost was $680921 of $86445642 total
health care plan costs.
In addition to its economic costs, infertility has a major
psychological impact. Oddens et al. reported that infertile
women had depressive and anxiety symptoms four times
more frequently than fertile women [8], and the rate is
comparable to women with cancer and coronary heart
disease[9].Thepresenceofsuchpsychologicaldisordersmay
have a negative impact on infertility treatment outcomes, as
it was reported that IVF success rates in the ﬁrst 5 cycles may
be lower in depressed women compared to the nondepressed
[10].
3.LimitationsofAssisted
ReproductiveTechnologies
In 2001 in the United States, 108130 ART cycles were carried
out in 385 programs, with 79042 cycles being IVF [11]. In
2003 in Europe, 365103 ART cycles were accomplished in
1008 clinics, with 132932 cycles being IVF [12]. Despite this
increase in the use of these treatment modalities, they are
still costly, invasive, and associated with drawbacks. In the
year 2001, the median cost of IVF in the US was extrapolated
to be $9226 per cycle and $56419 per delivery. Outside
the US, this cost was calculated to be $3531 per cycle and
$20522 per delivery [13] .T h eh i g hc o s to fI V Fd e e p e n so n
the gap between the number of IVF cycles performed and
the treatment needs of infertile couples.
In addition to its costs, the use of IVF is associated
with other undesirable outcomes. These include preterm
delivery, leading to increased risk of newborn prematurity
and its concomitant costs and morbidity, and increased rates
of multiple gestations [14]. In the US, in the year 2003,
48756 infants were born from ARTs, accounting for 1% of
all births. Fifty-one percent of this number resulted from
multiple gestations. Furthermore, the incidence of low birth
weight and preterm delivery among singleton infants born
from ARTs were 9% and 15%, respectively, while low birth
weight occurred in 94% among triplets and higher order
multiple gestations [15]. In a meta-analysis to assess the
perinatal outcome in singletons following IVF [16], Jackson
et al. reported increased fetal risks of preterm birth, low and
very low birth weights, small for gestational age, neonatal
intensive care unit admissions, stillbirth, neonatal mortality,
and cerebral palsy as well as increased maternal risks of
pre-eclampsia, placenta previa, gestational diabetes, and
caesarean delivery. Furthermore, there may be an increased
incidence of major birth defects (renal and musculoskeletal)
and autosomal reciprocal-balanced translocations among
infants born after IVF/ICSI compared to naturally conceived
infants [17, 18].
4. Limitationsof IUI
The limitations of IUI are few. They included the potential
risk of infection from uterine catheterization and injection
of the semen specimen. However, this risk has been reported
to be 0.01–0.2%. In addition, ectopic pregnancies and spon-
taneous miscarriages may occur, which is not diﬀerent from
other infertility treatment modalities [19]. The production
of antisperm antibodies is another hypothetical drawback
of the use of IUI. The incidence of multiple pregnancy
and ovarian hyperstimulation syndrome (OHSS) with IUI
may occur and is related to the use of ovarian stimulation
with IUI. The risk of OHSS may be decreased by use of
low-dose drug regimens, close monitoring, and strict cycle
cancellation criteria.
Regarding the perinatal outcomes of IUI conceptions,
Gaudoin et al. reported in a retrospective cohort study that
ovulation induction combined with IUI was associated with
increased risk of preterm birth and low birth weight [20].
However, other studies did not describe such associations
[21, 22].
5. Effectivenessof IUI
The pregnancy rate of IUI is reported to 10–20% per
patient, but the reported rates range from as low as 5% to
as high as 70% [23]. Based on the etiology of infertility,
the highest rates were reported when IUI was used in
patients with anovulation who were undergoing ovulation
induction therapy at the time of the IUI treatment, male
factor infertility, and unexplained infertility. In patients with
endometriosis, the pregnancy rates were the lowest [24].
The number of mature follicles (17mm in diameter or
more) is another prognostic factor in IUI success, where the
presence of 3-4 mature follicles was associated with higher
pregnancyratesandalowerincidenceofhigh-ordermultiple
pregnancies [25]. Other prognostic factors included female
age, infertility duration and amount of motile sperm [26].
The cost eﬀectiveness of IUI has been studied. In a
retrospective cohort study [27], Van Voorhis et al. reported
$8674 as the cost per delivery for IUI alone, $7808
for clomiphene combined with IUI, $10282 for human
menopausal gonadotropin (hMG) combined with IUI and
$43138 for IVF. The authors supported the use of IUI (any
modality) as being cost eﬀective, before ART, for infertile
couples with patent tubes, female age 38 years or less, and a
sperm count of 10 × 106 motile spermatozoa in a post washObstetrics and Gynecology International 3
sample. For those with blocked tubes, IVF-ET was found
to be a cost-eﬀective practice compared to surgery. In a
prospective study, based on cost eﬀectiveness, Karande et al.
did not recommend IVF as ﬁrst-line option for infertile
couples [28]. In a prospective-randomized study, Goverde
et al. found that IUI was as eﬀective as and less costly
than IVF in treatment of unexplained and male factor
infertility [29]. Peterson et al. reported that four cycles of
controlled ovarian hyperstimulation (COH) combined with
IUI were superior to IVF and less expensive than single
IVF cycle [30]. Even when the same stimulation protocols
were used, the cost per pregnancy for IUI was less than
half that of IVF [31]. Cohlen et al. conducted a Cochrane
review to analyze the eﬀectiveness of IUI versus timed
intercourse both in natural and stimulated cycles in cases
of male factor infertility [32]. A search of Medline (January
1966-present), EMBASE (http://www.embase.com/), DDFU
(http://www.ovid.com/site/catalog/DataBase/893.jsp?top=2
&mid=3&bottom=7&subsection=10),BIOSIS(Philadelphia,
USA), SCI (http://www.thomsonreuters.com/products serv-
ices/scientiﬁc/Science Citation Index Expanded) and hand
searching of references from identiﬁed studies resulted in
43 studies related to research topic being retrieved. They
used 17 studies in the systematic review and their data
were pooled in the meta-analysis. In their ﬁnal conclusions,
Cohlen et al. reported that IUI with COH was more cost-
eﬀective compared to IVF [32]. A more recent study, by
Pashayan et al., however, oﬀered evidence that IVF as a
ﬁrst-line treatment for couples with unexplained and mild
male factor infertility was less costly than IUI followed by
IVF (for IUI treatment inability to achieve pregnancy) [33].
6. The Use of IUI andConcurrent
OvarianStimulation
W h i c hi sm o r ee ﬀe c t i v e :I U Ii nan a t u r a lc y c l eo rc o m -
bined with ovarian stimulation? In a meta-analysis that
includedonlyrandomizedcontrolledtrials,Hughesreported
a signiﬁcant improvement in fecundity with the use of
IUI and follicle stimulating hormone (FSH). He found
more than two-fold increase in fecundability for either
IUI or FSH treatment alone, while he found a ﬁve-fold
increase when IUI and FSH are combined together [34].
In the Cochrane review by Cohlen et al. referenced above,
conducted to assess the eﬀe c t i v e n e s so fI U Iv e r s u st i m e d
intercourse [32], IUI in a natural cycle was compared to
IUI combined with controlled ovarian hyperstimulation.
Data from four trials were included in the meta-analysis
for this comparison. Although there was no signiﬁcant
diﬀerence between IUI in natural cycles and IUI combined
with ovarian hyperstimulation in cases with male factor
infertility, the results suggested increased conception with
ovarian hyperstimulation (odds ratio: 1.8 with CI: 0.98–
3.3). In their conclusion, Cohlen et al. recommended the
u s eo fI U Ii nn a t u r a lc y c l e sf o rc a s e sw i t hs e v e r es e m e n
defect (a total motile sperm count of less than 10 ×
106, but with more than 1 × 106 motile sperm after
preparation). In cases of less severe semen defect, IUI
with ovarian hyperstimulation was recommended. A large
randomized study in the US conﬁrmed the eﬀectiveness of
combining ovarian stimulation with IUI [35]. The study
reported an overall pregnancy rate per couple of 33% for
IUI with ovarian stimulation and an overall pregnancy
rate of 18% for IUI alone. Data of this study were
included in the Cochrane review, discussed above, which
was accomplished to assess the eﬀectiveness of IUI in the
treatmentofunexplainedinfertility.Verhulstetal.conducted
a Cochrane review to assess the eﬀectiveness of IUI in
the treatment of unexplained infertility [36]. Their primary
search yielded 198 articles related to the topic, but hand
searching of their abstracts resulted in 25 trials included in
the review. It was found that live birth rate per couple was
signiﬁcantly higher when IUI was combined with ovarian
hyperstimulation compared to IUI alone (OR 2.07, 95% CI:
1.22–3.5) [36]. However, this review did not ﬁnd studies
assessing expectant management versus IUI in unexplained
infertility. At the same year of publication as the above
Cochrane review, Steures et al. published a randomized
clinical trial comparing ovarian hyperstimulation combined
with IUI versus expectant management for couples with
unexplained infertility [37]. This study reported no higher
pregnancyratesforovarianhyperstimulationcombinedwith
IUI overexpectant management in couples with unexplained
infertility.
The National Institute for Clinical Excellence (NICE) in
the United Kingdom recommended, with level I evidence,
that when IUI is used to treat male factor infertility, ovarian
stimulationshouldnotbeoﬀered.Thisconclusionwasbased
on two trials [29, 32]. Supporting this recommendation
is the results of a randomized clinical trial conducted in
the Netherlands by Steures et al. [38]. This study reported
similar pregnancy rates when IUI alone or IUI combined
with ovarian hyperstimulation were used to treat couples
with abnormal postcoital tests and poor prognosis for
spontaneous pregnancy. For unexplained infertility, both
IUI alone and IUI combined with ovarian hyperstimulation
appear to be more eﬀective than expectant management
alone [39].
What drugs should be used for ovarian hyperstim-
ulation combined with IUI? Gonadotropins with and
without gonadotropin-releasing hormone (GnRH) ago-
nist/antagonist have been studied, along with recombinant
humanFSH(rFSH).Ragnietal.reportedthatthedailyuseof
50 IU of rFSH, combined with a GnRH antagonist, ganirelix,
for ovarian stimulation prior to IUI resulted in a live birth
rate per couple of 25.7% [40]. When the same dose of rFSH
was used on alternate days, rFSH produced a live birth rate
of 2.9% [40] .I na n o t h e rs t u d y ,5 0I Ud a i l yo fr F S Hw a s
found similar to 75 IU daily of urinary FSH (uFSH) in the
outcomes of the number of follicles >17mm and days of
stimulation[41].Theclinicalpregnancyrateswere12.7%for
rFSH and 11.9% for uFSH [41]. Thus, the more expensive
rFSH was not a cost-eﬀective drug for induction of ovulation
in IUI cycles. Conversely, Demirol and Gurgan compared
rFSH to uFSH and hMG in IUI cycles, and found rFSH and
IUI produced a clinical pregnancy rate of 25.9% compared
to 13.8% for uFSH and 12.5% for hMG [42]. When rFSH4 Obstetrics and Gynecology International
and clomiphene citrate (CC) were compared for ovulation
induction with IUI in couples with unexplained and male
factor infertility, the cumulative pregnancy rate was 38%
for CC-IUI group versus 34.3% for the rFSH-IUI group
[43].
Recently Cantineau and Cohlen performed a Cochrane
review to evaluate diﬀerent ovarian stimulation protocols
(antiestrogens, aromatase inhibitors, and gonadotropins
with or without GnRH agonists/antagonists) [44]. All pub-
lished randomized controlled trials (RCTs) comparing dif-
ferent stimulation protocols before IUI were searched in
the Menstrual Disorders and Subfertility group’s Central
register of the Controlled Trials, Medline, and EMBASE. 81
studies were identiﬁed, but only 43 trials met the inclusion
criteria. Of the diﬀerent comparisons done in this review,
l e t r o z o l ew a sn o tm o r ee ﬀective than CC (OR 1.2, 95%
CI: 0.64–2.1). The analysis also revealed that gonadotropins,
in low-dose regimens (50–75 IU), were the most eﬀective
agents when ovarian stimulation was combined with IUI.
Although less eﬀective than gonadotropins, antiestrogens
were more cost eﬀective in IUI therapy. Neither a higher
dosage (>75IU gonadotropins) nor the addition of GnRH
agonists was more eﬀective. Conversely, the higher dosage
and the GnRH agonists were associated with increased
costs and risks of multiple gestations and of OHSS. A
systematic review by Costello assessed the eﬀectiveness of
CC and IUI in the treatment of ovulatory infertility [45].
Seven RCTs were included in this review. The meta-analysis
of this review showed a cycle pregnancy rate of 14.3%
for CC combined with IUI versus 6.4% for natural cycle
IUI.
Considerations in Technology-Limited Settings . The evidence
reviewed suggests that oral clomiphene therapy combined
with IUI or natural cycle IUI is satisfactory ﬁrst-line
choices for treatment of unexplained and male infertility
in low-technology settings. The combination of IUI and
controlledovarianhyperstimulationmayresultinarelatively
higher therapeutic pregnancy rate for unexplained and for
male infertility. Gonadotropins are the controlled ovarian
hyperstimulation agents that result in the highest rates
of pregnancy. However, the costs associated with these
drugs are higher, and the serum steroid measurements
and ultrasonographic monitoring require higher levels of
technological capabilities.
7. Semen Parametersandthe Use of IUI
The WHO criteria for normal semen parameters are widely
used [46]. In the system, an abnormal semen count is
deﬁned as deviations from the normal criteria on two con-
secutive semen analyses [46]. Studies have examined semen
parameters, like motile sperm concentration and normal
sperm morphology, in relation to IUI outcome (Table 1).
In Table 1, four inferences could be made: most of the
studies are retrospective, the number of insemination cycles
is fewer in the prospective studies, all but one study used the
inseminatedmotilespermcountafterspermpreparationand
the studies reported on diﬀerent outcome measurements. In
spite of the limitations outlined above, it may be deduced
that reasonable IUI success rates can still be obtained in
casesofseveresemendefects(normalmorphology4%orless
and inseminated sperm count as low as one million). This
supports the need for large well-designed prospective studies
using standard outcomes.
Regarding sperm concentration, Ombelet et al. in a
retrospective study found that when inseminated motile
sperm count was > 1 × 106, clomiphene-IUI resulted in a
baby take-home rate of 21–25% after 3 cycles [47]. Even
when inseminated motile sperm count was < 1 × 106
and the normal sperm morphology >4%, clomiphene-IUI
remained a treatment choice that resulted in pregnancies. In
aretrospectiveanalysisof3479IUIcyclesconductedfor1039
infertile couples [48], Van Voorhis et al. found that a total
motile sperm count per specimen of less than 10 million was
associated with lower pregnancy rates. On the other hand, a
total motile sperm count above 10 million did not produce a
signiﬁcant increase in IUI pregnancy rates.
Cohlen et al. deﬁned a total motile sperm count per
ejaculate between 5 and 10 × 106 to be a severe semen
defect [49]. They reported a pregnancy rate per IUI cycle of
12% for couples with that count. Wainer et al. reported on
the number of motile sperm inseminated [50]a n df o u n da
clinical pregnancy rate per cycle of 3.13% when the number
of motile sperm inseminated was < 1 × 106. When the
number of motile sperm inseminated was between 5 and
10 × 106, the clinical pregnancy rate per cycle was 14%.
Miller et al. reported a cutoﬀ point for number of motile
sperm inseminated after sperm preparation as 10 ×106 [51].
Berg et al. reported successful pregnancies in patients after
controlled ovarian stimulations in IUI preparations with
motile sperm counts as low as >0.8 ×106 [52].
Normal sperm morphology as a predictor of IUI success
has been examined. After controlling for sperm concentra-
tion and motility, Lee et al. found that the normal sperm
morphology,usingKruger’sstrictcriteria[53],morestrongly
predicted IUI outcome [54]. They reported pregnancy
rates per cycle of 3.8% in couples with <4% of Kruger’s
strict criteria normal morphology, 18.5% for Kruger’s strict
criteria normal morphology of 4–9% and 29.9% when
Kruger’s strict criteria normal morphology was above 9%
[54]. These results were similar to those reported in a study
by Hauser et al. [55], where CC-IUI resulted in a pregnancy
rates per couple of 11.1% when normal morphology by strict
criteria was less than 4%, 36.1% for normal morphology
of 4–14% and 50% when normal morphology was above
14%. The link between sperm motility and IUI success
was addressed in several studies. Brieﬂy, in these studies,
total motile sperm of 30–50% before sperm preparation was
found to be associated with positive IUI outcomes [54, 56,
57].
Considerations in Technology-Limited Settings. The evidence
reviewed suggests that IUI may be oﬀered to couples with
male factor infertility, in a low technology setting, if the total
motile sperm count is more than 5 million per specimen.Obstetrics and Gynecology International 5
Table 1: Motile sperm concentration, normal morphology, and IUI outcome.
Author Year
Design
(prospective or
retrospective)
Number of
infertile
patients
Number of
insemination
cycles
IMSC
(million)
Normal
morphology
IUI
outcome
Total motile
sperm
count∗10/6
(before wash)
Ombelet et al. 1997 Retrospective 373 792 <1 <4% 0% CF
<1 >4% 7.8%
>1 >4% 15%
Van Voorhis et al. 2001 Retrospective 1,039 3,479 PR 2.3% <10
PR 9% >10
Cohlen et al. 1998 Prospective 74 308 <1P R 2 . 6 %
>1 PR 11.2%
Wainer et al. 2004 Retrospective 889 2,564 <1 >30% PR 3.1%
2–5 PR 12%
Dodson & Haney 1991 Retrospective 371 808 <1C F 0 %
1–5 CF 17%
Horvath et al. 1989 Prospective 232 451 <1C F 2 . 6 %
>10 CF 11.6%
Berg et al. 1997 Retrospective 902 3,037 0.8–1.2 PRcy 8.2%
>5 10%
Miller et al. 2002 Prospective 438 1,114 <10 CF 1%
10–20 CF 7.4%
>20 CF 12.4%
Irianni et al. 1993 Retrospective 129 208 >4.7 PR 14%
Toner et al. 1994 Prospective 126 395 104 9% PRcy 9%
Lindheim et al. 1996 Retrospective 42 <4% PRcy 1%
>4% PRcy 19%
Montanaro Gauci et al. 1999 Retrospective 273 522 <4% PRcy 2.6%
5–14% 11%
>14% 24%
Shibahara et al. 2004 Prospective 160 682 >15% PRcy 15%
Hauser et al. 2001 Prospective 108 264 <4% 4-PRcp
11%
14% 36%
>14% 50%
Lee et al. 2002 Prospective 209 244 <4% PRcy 3.8%
4–9% 18.5%
>9% 30%
Dickey et al. 1999 Retrospective 1,841 4,056 <5% PRcy 0%
>5% 11%
Dickey et al. 1999 Retrospective 1,841 4,056 PRcy 2.3% <5
8.5% >5
CF: Cycle fecundity; IMSC: Inseminated motile sperm count; PR: Overall pregnancy rate; PRcy: Pregnancy rate per cycle; PRcp: Pregnancy rate per couple.6 Obstetrics and Gynecology International
8. Sperm Preparation Methods
The aim of semen preparation is to separate motile, mor-
phologically normal spermatozoa from the seminal plasma
and from debris such as leucocytes, bacteria, and nonmotile
spermatozoa. Table 2 shows studies that addressed the eﬀect
of diﬀerent sperm preparation methods on IUI outcome. As
shown in the table, the number of these studies is limited.
Sperm wash, swim-up, and density gradient centrifugation
are the most commonly used methods. As shown in
Table 2, density gradient centrifugation was associated with
acceptable IUI outcomes [58–62]. Swim-up as a procedure is
also associated with satisfactory IUI outcomes, comparable
to density gradient centrifugation pregnancy rates. Further-
more, other studies (the preparation technique was not
the primary question addressed) reported similar outcomes
for both methods [47, 50]. Boomsma et al. conducted a
Cochrane review to compare the eﬀectiveness of the three
diﬀerent semen preparation techniques (conventional wash,
swim-up procedure, and density gradient centrifugation)
before IUI [63]. Only two RCTs could be included in the
meta-analysis regarding the clinical outcomes. This resulted
in insuﬃcient data to recommend anyone of the three semen
preparation techniques over the others.
The time intervals between semen collection, sperm
processing, and insemination may aﬀect IUI outcomes.
Yavas and Selub performed a retrospective study where the
collection of semen at the clinic was found to be better than
at home. Short intervals from semen collection to sperm
wash, from sperm wash to IUI, and from semen collection to
IUIwereassociatedwithhigherpregnancyratescomparedto
semen collection at home with longer time intervals [64].
Considerations in Technology-Limited Settings. The evidence
suggests that conventional sperm wash for IUI can be used
in a low-technology setting. The evidence does not seem
to show that anyone of the three commonly used sperm
preparation methods results in a higher pregnancy rate than
any other.
9. Timing of IUI
Normalspermiscapableoffertilizinganoocyteinthefemale
genital tract for about 5 days, and an oocyte is fertilizable
for 12–24 hours after ovulation [65]. The WHO conducted
a large multicenter study that concluded that ovulation
occurred between 24 and 56 hours (average 32 hours) after
the onset of luteinizig hormone (LH) surge [66]. In another
study ovulation, occurred 36–38 hours after the onset of LH
surge in natural cycles [67]. The LH surge can be detected at
home using urinary LH kits. The monitoring for the urinary
LH surge can start about 3 days before the expected date of
ovulation. Generally, in natural cycles, IUI can be performed
24 hours after the onset of LH surge as detected by urinary
LH monitoring.
In controlled ovarian stimulation cycles in which ovu-
lation is triggered artiﬁcially, ovulation occurs 32–38 hours
after human chorionic gonadotropin (HCG) injection [68,
69]. Based on the available data about the timing of ovu-
lation, some investigators recommended that insemination
can be carried out between 12 and 60 hours after HCG
injection [70–72]. Other investigators found that delayed
inseminations to 38–40 hours after HCG injection were
associated with higher pregnancy rates compared to early
inseminations [73].ThiswasnotfoundinastudybyClaman
et al., who found that there was no signiﬁcant diﬀerence in
pregnancy rates between early (32–34 hours) and late (38–40
hours)inseminations[74].WhenHCGisused,insemination
can be done 34–40 hours after injection [75].
A systematic review was performed by Kosmas et al.
to compare the eﬀectiveness of HCG administration versus
urinary LH detection as a method of IUI timing after
CC stimulation [76]. Seven studies were included in this
systematic review and the meta-analysis. The authors found
that the use of urinary LH monitoring as a method of
IUI timing was associated with higher pregnancy rates than
the HCG administration method. They concluded that LH
monitoring for IUI timing is more practical, eﬀective, and
cost-eﬀective when CC is used for ovarian stimulation [76].
Considerations in Technology-Limited Settings. The evidence
suggests that it is reasonable to perform IUI, for either
natural cycle IUI or for clomiphene combined with IUI,
approximately 24 hours after the detection of the LH surge.
Urine testing kits could be used to detect the LH surge.
10. Number of Inseminations per Cycle
Several studies have compared single versus double IUIs in
an ovulatory cycle. One of the earlier studies, conducted
for that purpose, reported a cycle fecundity of 52% when 2
inseminations 18 and 42 hours after HCG were performed
while a single insemination performed 34 hours after
HCG injection resulted in a cycle fecundity of 8.7% [71].
Another study found that double inseminations, performed
12 and 34 hours after HCG administration, in gonadotropin
stimulated cycles, resulted in a pregnancy rate per patient of
30.4%, a higher pregnancy rate than that found from single
inseminations (14.4%) performed 34 hours after HCG [72].
On the other hand, Ransom et al. found no diﬀerence
in pregnancy rates between single IUI performed 35 hours
after HCG and double IUI done 19 and 43 hours after HCG
injection [77]. These results were supported in a study by
Alborzi et al. [78] where pregnancy rates per cycle were
8.6% and 9.4% (nonsigniﬁcantly diﬀerent) for single and
double IUIs. Another study, by Casadei et al., failed to show
a signiﬁcant advantage of double inseminations 12 and 36
hours after HCG injection over single insemination done 36
hours after HCG [79].
Two reviews were conducted to reach a conclusion about
the number of inseminations per cycle [80]. One was a
systematic review and meta-analysis [80] and the second
was a Cochrane analysis [81]. In the ﬁrst review, by Osuna
et al., 18 trials were retrieved from searching Medline, The
Cochrane library, and the abstract books of annual meetings
of ESHRE and ASRM [80]. Only six randomized prospectiveObstetrics and Gynecology International 7
Table 2: Sperm preparation methods.
Author Year Design (prospective
or retrospective)
Number of
infertile patients
Number of
insemination cycles
Method of
preparation IUI outcome
Carrell et al. 1998 Prospective 363 898
Sperm wash PR 8.9%
-Swim-up 14.7%
-Swim-down 7.7%
-Percoll density
gradient
16.1%
-Sperm refriger-
ation/heparin
incubation
11%
Dodson et al. 1998 Prospective 80 153
Double
cenrifugation
CF 15%
-Swim-up 14%
-Percoll density
gradient
20%
Morshedi et al. 2003 Prospective 311 676 Simple wash PR 11.6%
-Density
gradient
14.3%
Lan et al. 2004 Prospective 140 NA
Swim-up PR 15%
-Percoll density
gradient
20%
-Wang’s tube
method
45%
Ren et al. 2004 Prospective NA 317
Albumin PR 12.5%
-Puresperm 7.4%
-Swim-up 9.6%
-Percoll density
gradient
12.7%
PR: Pregnancy rate; CF: Cycle fecundity; NA: Not available.
studies were included in the review. The pooled outcomes
of the studies were a pregnancy rate per cycle of 14.9% for
doubleIUIsversus11.4%forasingleIUI.Thisdiﬀerencewas
statisticallyinsigniﬁcant.TheCochranereview,byCantineau
et al., followed the same search strategies and data analyses
as mentioned previously [81]. From the 30 studies retrieved,
13 were found to provide data comparing single versus
double inseminations. Only 3 RCTs were included in the
review, the results of 2 of them were pooled for meta-
analysis. The authors concluded that there was no evidence
that double inseminations give rise to higher live birth
rates in infertile couples compared to single inseminations
(OR 1.45, CI: 0.78–2.7). The NICE recommendation is
for a single insemination when oﬀering IUI as therapy
[39].
Considerations in Technology-Limited Settings. The evidence
suggests that single IUI insemination per ovulatory cycle
should be considered. Published evidence does not support
that two IUI in a single cycle results in a higher rate of
pregnancy. A single insemination will be less costly, with
similar pregnancy outcomes.
11. Number of Insemination Cycles
Some studies report six treatment cycles [29, 60, 78], while
others report four cycles [35, 82] as the number of cycles
of treatment with IUIs. One study reported a cumulative
probability of pregnancy of 38.2% for 6 treatment cycles
and 49.5% for 10 treatment cycles [52]. One of the six-
cycle studies, by Morshedi et al., reported that 88% of the
pregnancies occurred in the ﬁrst 3 cycles [60]. However, a
Cochrane review and the NICE guidelines support using IUI
as treatment for up to 6 cycles [32, 83]. The NICE reported,
with level I evidence, that the use of up to 6 cycles on IUI
increased the chance of pregnancy for couples with mild
male-factor and unexplained infertility and minimal to mild
endometriosis. The Cochrane reviewers concluded that most
pregnancies occurred during the ﬁrst 3 to 6 IUIs treatment
cycles.
Considerations in Technology-Limited Settings. The evidence
suggests performing a minimum of three IUI treatment
cycles and a maximum of six IUI treatment cycles in
technology-limited setting.8 Obstetrics and Gynecology International
12. Conclusion
The resource allocation of infertility services available for
patients is asymmetric, with the highest levels in the larger
cities. The evidence reviewed suggests that IUI may be
helpful in a low-technology medical setting. It may be
considered as a good ﬁrst-line treatment for couples with
unexplained infertility, male factor infertility, and anovu-
lation (IUI used concurrently with ovulation induction).
In the clinical practice of IUI in a low-technology setting,
combining oral clomiphene with IUI is as reasonable of
an option as natural cycle IUI. For semen parameters, a
motile sperm count above 1 million in the ﬁnal specimen
can serve as a cutoﬀ point for oﬀering IUI. Conventional
sperm washing, density gradient centrifugation, or swim-
u pt e c h n i q u e sc a na l lb eu s e df o rs p e r mp r e p a r a t i o nb e f o r e
IUI, with conventional sperm washing being the simplest. A
single IUI per cycle should be performed, and the IUI can be
performed approximately 24 hours after urinary LH surge is
detected. Couples may be oﬀe r e d3t o6I U Ic y c l e st oe n s u r e
suﬃcient opportunity to achieve pregnancy.
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